Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

CLL / SLL Expert Healthcare Providers

Although CLL / SLL is the most common type of adult blood cancer, it is still considered a rare (orphan) disease. Treatments have changed radically in the last few years, and it is difficult for even dedicated blood cancer experts to stay on top of the latest advances. Having a CLL / SLL expert as part of your healthcare team, in addition to your local healthcare provider, has been directly connected to a survival advantage.

There is no definition or set criteria for who qualifies to be a CLL / SLL expert. However, those listed below have been put through CLL Society’s vetting process to ensure they meet certain standards that we feel are important to help ensure patients get their best care. 

Here are some of the important criteria CLL Society takes into consideration when determining who to include on the expert list:

1) Does the individual regularly encourage their patients to participate in clinical trials?

2) Do they perform the critically necessary biomarker testing before deciding upon any treatments for CLL / SLL?

3) Do they primarily prescribe treatment regimens that are considered the most current standard of care (i.e., avoid prescribing chemoimmunotherapy for their CLL / SLL patients except for extremely rare circumstances)? 

4) Is a good percentage of those they are regularly seeing in their office patients with CLL / SLL? 

Please Note: The list of healthcare providers below is not exhaustive of every single CLL and SLL expert out there. However, the list is a great place to begin researching which expert might be the best fit for you.

Find a local CLL expert if possible. Otherwise, consider traveling to a consult and establish a relationship or consider using our


Patient, Know Thyself Mark Hoffman is a long-time CLL patient advocate and facilitator of the CLL Society Patient & Caregiver Support Group in San Diego, CA. In this article from Cancer Health, Mark echoes the importance of the Test Before Treat™ campaign by sharing his story. When Mark was
(Expert Access & Test Before Treat™) This is just a brief note to tell you about the important impact you had on my treatment for CLL. Last November, through the Expert Access program sponsored by the CLL Society, you were kind enough to review my medical records and chat
When I was first diagnosed in April 2018, my WBC was at 55k, my local Hematologist performed the FISH test and found out I had 11Q with loss of ATM, they told me that only made a difference in the type of treatment I would need and I probably
Diagnosed Aug 2018 as a 54-year-old female, with SLL via node biopsy. CT showed extensive lymphadenopathy, very bulky disease, particularly in mesentery. Bloodwork all in normal range. Had BMB in spring 2019 for purposes of FISH. Had been experiencing increasing fatigue and discomfort in gut. Pathologist decided not to
I question if my doctor should have genetic tested me before treating me with Bendamustine in December 2013 and if this was the cause of my developing theTP53 mutation after my initial diagnosis of 13q in 2008. After the Bendamustine treatments, I started on Ibrutinib in January 2014. Gary
I was diagnosed accidentally in 2001 during investigation of a single swollen cervical node. My community oncologist at Maine Medical Center recommended chemo immediately. A comprehensive second opinion from Dana Farber led to 15 years of asymptomatic watch and wait. In 2015 a dramatic appearance of symptoms over 3